Home » Topics » Disease categories and therapies » Infection

Infection
RSS

Micrologix Biotech initiates phase I trial in U.S. with MBI-226

Dec. 10, 1998

LY-303366: therapeutic and prophylactic efficacy in pulmonary aspergillosis in neutropenic animals

Dec. 9, 1998

Water-soluble antifungal agents enter the pipeline at Takeda

Dec. 8, 1998

Japanese lab prepares new, broad-spectrum carbapenems

Dec. 7, 1998

Potent antifungal triazoles reported by Sankyo

Dec. 7, 1998

Potent anti-MRSA agents developed by Sankyo

Dec. 4, 1998

Ascent to terminate copromotion agreement with Bristol-Myers Squibb

Dec. 4, 1998

Ascent to promote Warner-Lambert's Omnicef

Dec. 3, 1998

Bausch & Lomb to manufacture Lidakol for treatment of oral-facial herpes

Dec. 3, 1998

AMBI seeks partners to develop injectable nisin for treatment of hospital-acquired infections

Dec. 3, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...